BusinessMRI Interventions’ ClearPoint® Neuro Navigation System Utilized in Voyager Therapeutics’ VY-AADC01 Phase 1b Trial; Positive Interim Results ReportedBy Nasdaq OMXDec 8, 2016, 2:00 PM UTC
BusinessMRI Interventions’ ClearPoint® Neuro Navigation System to be Exhibited at Pediatric Neurosurgical ConferenceBy Nasdaq OMXDec 5, 2016, 2:00 PM UTC
BusinessMats Wahlström Joins Surefire Medical Board of DirectorsBy Nasdaq OMXNov 30, 2016, 11:00 AM UTC
BusinessEyenovia, Inc. announces publication of Phase II study results demonstrating benefits of micro-formulation over conventional eyedroppers and addition of Scientific Advisory Board membersBy Nasdaq OMXNov 28, 2016, 8:47 PM UTC
BusinessMRI Interventions’ ClearPoint® Neuro Navigation System to be Featured at the American Epilepsy Society MeetingBy Nasdaq OMXNov 28, 2016, 11:00 AM UTC
BusinessCapsoVision, Inc. Announces FDA 510(k) Clearance for CapsoCam® PlusBy Nasdaq OMXNov 11, 2016, 8:44 PM UTC
BusinessMRI Interventions, Inc. Announces 2016 Third Quarter and Nine Month ResultsBy Nasdaq OMXNov 4, 2016, 1:00 PM UTC
